This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2 Mar 2012

Abbott & Galapagos Announce Collaboration for Arthritis Drug

Abbott Laboratories has made a development agreement with Galapagos for a mid-stage rheumatoid arthritis medication.

Abbott Laboratories and Belgian drug developer Galapagos have announced a collaboration to develop Galapagos' GLPG0634, a mid-stage rheumatoid arthritis medication.


GLPG0634, a Janus kinase-1 inhibitor, is currently under development and has reported results from a four-week Phase IIa study in which the drug demonstrated efficacy measures amongst the best reported in rheumatoid arthritis.


Abbott has paid an initial $150m for the drug, with Galapagos due to receive a further payment of $200m upon the completion of further Phase II studies into the drug. Galapagos will retain the rights to co-promote the drug in Belgium, Netherlands and Luxembourg.


Galapagos will also be eligible to receive miles

Related News